146 related articles for article (PubMed ID: 37391408)
1. Notch1 promotes resistance to cisplatin by up-regulating Ecto-5'-nucleotidase (CD73) in triple-negative breast cancer cells.
Qi Y; Li M; Li S; Zeng D; Xiao Y; Li J; Ye Q; Bremer E; Zhang GJ
Cell Death Discov; 2023 Jun; 9(1):204. PubMed ID: 37391408
[TBL] [Abstract][Full Text] [Related]
2. Major vault protein is a direct target of Notch1 signaling and contributes to chemoresistance in triple-negative breast cancer cells.
Xiao YS; Zeng D; Liang YK; Wu Y; Li MF; Qi YZ; Wei XL; Huang WH; Chen M; Zhang GJ
Cancer Lett; 2019 Jan; 440-441():156-167. PubMed ID: 30336197
[TBL] [Abstract][Full Text] [Related]
3. CD73 promotes anthracycline resistance and poor prognosis in triple negative breast cancer.
Loi S; Pommey S; Haibe-Kains B; Beavis PA; Darcy PK; Smyth MJ; Stagg J
Proc Natl Acad Sci U S A; 2013 Jul; 110(27):11091-6. PubMed ID: 23776241
[TBL] [Abstract][Full Text] [Related]
4. Additive Pharmacological Interaction between Cisplatin (CDDP) and Histone Deacetylase Inhibitors (HDIs) in MDA-MB-231 Triple Negative Breast Cancer (TNBC) Cells with Altered Notch1 Activity-An Isobolographic Analysis.
Wawruszak A; Luszczki JJ; Kalafut J; Okla K; Halasa M; Rivero-Muller A; Stepulak A
Int J Mol Sci; 2019 Jul; 20(15):. PubMed ID: 31357442
[TBL] [Abstract][Full Text] [Related]
5. SNAI1-dependent upregulation of CD73 increases extracellular adenosine release to mediate immune suppression in TNBC.
Hasmim M; Xiao M; Van Moer K; Kumar A; Oniga A; Mittelbronn M; Duhem C; Chammout A; Berchem G; Thiery JP; Volpert M; Hollier B; Noman MZ; Janji B
Front Immunol; 2022; 13():982821. PubMed ID: 36159844
[TBL] [Abstract][Full Text] [Related]
6. Targeting CD73 and downstream adenosine receptor signaling in triple-negative breast cancer.
Allard B; Turcotte M; Stagg J
Expert Opin Ther Targets; 2014 Aug; 18(8):863-81. PubMed ID: 24798880
[TBL] [Abstract][Full Text] [Related]
7. Comparative characterisation of an ecto-5'-nucleotidase (CD73) in non-tumoral MCF10-A breast cells and triple-negative MDA-MB-231 breast cancer cells.
Rocha-Vieira TC; Lacerda-Abreu MA; Carvalho-Kelly LF; Santos-Araújo S; Gondim KC; Meyer-Fernandes JR
Cell Biol Int; 2024 Jun; ():. PubMed ID: 38894528
[TBL] [Abstract][Full Text] [Related]
8. Tribbles Homolog 3 Involved in Radiation Response of Triple Negative Breast Cancer Cells by Regulating Notch1 Activation.
Lee YC; Wang WL; Chang WC; Huang YH; Hong GC; Wang HL; Chou YH; Tseng HC; Lee HT; Li ST; Chen HL; Wu CC; Yang HF; Wang BY; Chang WW
Cancers (Basel); 2019 Jan; 11(2):. PubMed ID: 30678233
[TBL] [Abstract][Full Text] [Related]
9. Clinical significance of CD73 in triple-negative breast cancer: multiplex analysis of a phase III clinical trial.
Buisseret L; Pommey S; Allard B; Garaud S; Bergeron M; Cousineau I; Ameye L; Bareche Y; Paesmans M; Crown JPA; Di Leo A; Loi S; Piccart-Gebhart M; Willard-Gallo K; Sotiriou C; Stagg J
Ann Oncol; 2018 Apr; 29(4):1056-1062. PubMed ID: 29145561
[TBL] [Abstract][Full Text] [Related]
10. c-Jun N-terminal kinase promotes stem cell phenotype in triple-negative breast cancer through upregulation of Notch1 via activation of c-Jun.
Xie X; Kaoud TS; Edupuganti R; Zhang T; Kogawa T; Zhao Y; Chauhan GB; Giannoukos DN; Qi Y; Tripathy D; Wang J; Gray NS; Dalby KN; Bartholomeusz C; Ueno NT
Oncogene; 2017 May; 36(18):2599-2608. PubMed ID: 27941886
[TBL] [Abstract][Full Text] [Related]
11. Notch Signaling Regulates Mitochondrial Metabolism and NF-κB Activity in Triple-Negative Breast Cancer Cells via IKKα-Dependent Non-canonical Pathways.
Hossain F; Sorrentino C; Ucar DA; Peng Y; Matossian M; Wyczechowska D; Crabtree J; Zabaleta J; Morello S; Del Valle L; Burow M; Collins-Burow B; Pannuti A; Minter LM; Golde TE; Osborne BA; Miele L
Front Oncol; 2018; 8():575. PubMed ID: 30564555
[TBL] [Abstract][Full Text] [Related]
12. miR-613 Suppresses Chemoresistance and Stemness in Triple-Negative Breast Cancer by Targeting FAM83A.
Liu C; Jiang Y; Han B
Cancer Manag Res; 2020; 12():12623-12633. PubMed ID: 33324107
[TBL] [Abstract][Full Text] [Related]
13. Tumor suppressor role of microRNA-1296 in triple-negative breast cancer.
Phan B; Majid S; Ursu S; de Semir D; Nosrati M; Bezrookove V; Kashani-Sabet M; Dar AA
Oncotarget; 2016 Apr; 7(15):19519-30. PubMed ID: 26799586
[TBL] [Abstract][Full Text] [Related]
14. Long non-coding RNA TUG1 sponges miR-197 to enhance cisplatin sensitivity in triple negative breast cancer.
Tang T; Cheng Y; She Q; Jiang Y; Chen Y; Yang W; Li Y
Biomed Pharmacother; 2018 Nov; 107():338-346. PubMed ID: 30098551
[TBL] [Abstract][Full Text] [Related]
15. Transcriptionally regulated miR-26a-5p may act as BRCAness in Triple-Negative Breast Cancer.
Zhang Y; Lv L; Zheng R; Xie R; Yu Y; Liao H; Chen J; Zhang B
Breast Cancer Res; 2023 Jun; 25(1):75. PubMed ID: 37365643
[TBL] [Abstract][Full Text] [Related]
16. ISL1 promotes cancer progression and inhibits cisplatin sensitivity in triple-negative breast cancer cells.
Zhang Y; Wang L; Gao P; Sun Z; Li N; Lu Y; Shen J; Sun J; Yang Y; Dai H; Cai H
Int J Mol Med; 2018 Nov; 42(5):2343-2352. PubMed ID: 30226569
[TBL] [Abstract][Full Text] [Related]
17. Sulforaphane-cisplatin combination inhibits the stemness and metastatic potential of TNBCs via down regulation of sirtuins-mediated EMT signaling axis.
Sinha S; Sharma S; Sharma A; Vora J; Shrivastava N
Phytomedicine; 2021 Apr; 84():153492. PubMed ID: 33640782
[TBL] [Abstract][Full Text] [Related]
18. CD73 facilitates EMT progression and promotes lung metastases in triple-negative breast cancer.
Petruk N; Tuominen S; Åkerfelt M; Mattsson J; Sandholm J; Nees M; Yegutkin GG; Jukkola A; Tuomela J; Selander KS
Sci Rep; 2021 Mar; 11(1):6035. PubMed ID: 33727591
[TBL] [Abstract][Full Text] [Related]
19. miR-638 mediated regulation of BRCA1 affects DNA repair and sensitivity to UV and cisplatin in triple-negative breast cancer.
Tan X; Peng J; Fu Y; An S; Rezaei K; Tabbara S; Teal CB; Man YG; Brem RF; Fu SW
Breast Cancer Res; 2014 Sep; 16(5):435. PubMed ID: 25228385
[TBL] [Abstract][Full Text] [Related]
20. FOXM1 transcriptionally regulates expression of integrin β1 in triple-negative breast cancer.
Hamurcu Z; Kahraman N; Ashour A; Ozpolat B
Breast Cancer Res Treat; 2017 Jun; 163(3):485-493. PubMed ID: 28361350
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
